Evidence map›Paper›PMID 31874419›Full record

ArticleAtherosclerosis2020

Transglutaminase 2 limits the extravasation and the resultant myocardial fibrosis associated with factor XIII-A deficiency.

Kathryn J Griffin, Laura M Newell, Kingsley R Simpson, Cora M L Beckers, Mark J Drinkhill, Kristina F Standeven, Lih T Cheah, Siiri E Iismaa, Peter J Grant, Christopher L Jackson and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Atherosclerosis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Kathryn J GriffinDiscovery and Translational Science Division, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, LS2 9JT, UK. Electronic address: k.j.griffin@leeds.ac.uk.
Laura M NewellBristol Heart Institute, University of Bristol, Bristol, BS2 8HW, UK.
Kingsley R SimpsonDiscovery and Translational Science Division, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, LS2 9JT, UK.
Cora M L BeckersDiscovery and Translational Science Division, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, LS2 9JT, UK.
Mark J DrinkhillDiscovery and Translational Science Division, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, LS2 9JT, UK.
Kristina F StandevenDiscovery and Translational Science Division, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, LS2 9JT, UK.
Lih T CheahDiscovery and Translational Science Division, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, LS2 9JT, UK.
Siiri E IismaaVictor Chang Cardiac Research Institute, Darlinghurst, NSW, 2010, Australia.
Peter J GrantDiscovery and Translational Science Division, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, LS2 9JT, UK.
Christopher L JacksonBristol Heart Institute, University of Bristol, Bristol, BS2 8HW, UK.
Richard J PeaseDiscovery and Translational Science Division, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, LS2 9JT, UK.
University of Leeds · GBUniversity of Bristol · GBVictor Chang Cardiac Research Institute · AU

Funding

British Heart Foundation FS/08/050/25667British Heart Foundation FS/11/91/29090British Heart Foundation FS/13/36/30243British Heart Foundation PG/11/96/29174British Heart Foundation PG/17/27/32928British Heart Foundation RG02/29261British Heart Foundation RG/12/8/29698
6 · The paper itself

Abstract

BACKGROUND AND

aimsTransglutaminase (TG) 2 and Factor (F) XIII-A have both been implicated in cardiovascular protection and repair. This study was designed to differentiate between two competing hypotheses: that TG2 and FXIII-A mediate these functions in mice by fulfilling separate roles, or that they act redundantly in this respect.

methodsAtherosclerosis was assessed in brachiocephalic artery plaques of fat-fed mixed strain apolipoprotein (Apo)e deficient mice that lacked either or both transglutaminases. Cardiac fibrosis was assessed both in the mixed strain mice and also in C57BL/6J Apoe expressing mice lacking either or both transglutaminases.

resultsNo difference was found in the density of buried fibrous caps within brachiocephalic plaques from mice expressing or lacking these transglutaminases. Cardiac fibrosis developed in both Apoe/F13a1 double knockout and F13a1 single knockout mice, but not in Tgm2 knockout mice. However, concomitant Tgm2 knockout markedly increased fibrosis, as apparent in both Apoe/Tgm2/F13a1 knockout and Tgm2/F13a1 knockout mice. Amongst F13a1 knockout and Tgm2/F13a1 knockout mice, the extent of fibrosis correlated with hemosiderin deposition, suggesting that TG2 limits the extravasation of blood in the myocardium, which in turn reduces the pro-fibrotic stimulus. The resulting fibrosis was interstitial in nature and caused only minor changes in cardiac function.

conclusionsThese studies confirm that FXIII-A and TG2 fulfil different roles in the mouse myocardium. FXIII-A protects against vascular leakage while TG2 contributes to the stability or repair of the vasculature. The protective function of TG2 must be considered when designing clinical anti-fibrotic therapies based upon FXIII-A or TG2 inhibition.

Indexed as

AnimalsApolipoproteins EAtherosclerosisDisease Models, AnimalFactor XIIIaFactor XIII DeficiencyFibrosisGTP-Binding ProteinsMaleMiceMice, Inbred C57BLMice, KnockoutProtein Glutamine gamma Glutamyltransferase 2TransglutaminasesApolipoproteins EFactor XIIIaGTP-Binding ProteinsProtein Glutamine gamma Glutamyltransferase 2TransglutaminasesAtherosclerosisFactor XIII-AFibrosisMyocardiumTransglutaminase 2

Identifiers

PMID31874419
PMCPMC7024992
OpenAlexW2995883118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.